Terms: = Ovarian cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Clinical Outcome
1 results:
1. Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.
Calabrese C; Frank A; Maclean K; Gilbertson R
J Biol Chem; 2003 Jul; 278(27):24951-9. PubMed ID: 12709419
[TBL] [Abstract] [Full Text] [Related]
